Get the Stockscreener App
10.57
1.54%
0.16
After Hours:
10.58
0.010
+0.09%
Evolent Health Inc stock is traded at $10.57, with a volume of 972.43K.
It is up +1.54% in the last 24 hours and down -3.73% over the past month.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
See More
Previous Close:
$10.41
Open:
$10.45
24h Volume:
972.43K
Relative Volume:
0.37
Market Cap:
$1.22B
Revenue:
$2.35B
Net Income/Loss:
$-74.42M
P/E Ratio:
-11.24
EPS:
-0.94
Net Cash Flow:
$150.93M
1W Performance:
+3.83%
1M Performance:
-3.73%
6M Performance:
-55.42%
1Y Performance:
-64.54%
1-Day Range:
$10.36
$10.66
1-Week Range:
$9.80
$10.69
52-Week Range:
$9.74
$35.00
Evolent Health Inc Stock (EVH) Company Profile
Name
Evolent Health Inc
Sector
Industry
Phone
571-389-6000
Address
800 NORTH GLEBE RD, SUITE 500, ARLINGTON
Compare EVH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
10.57 | 1.22B | 2.35B | -74.42M | 150.93M | -0.94 |
|
VEEV
Veeva Systems Inc
|
237.03 | 38.53B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
75.31 | 13.03B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
58.97 | 11.12B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
110.57 | 9.53B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
57.19 | 9.02B | 640.44M | -743.28M | -206.93M | -11.29 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Needham | Buy |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Nov-08-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-09-24 | Upgrade | Truist | Hold → Buy |
| Apr-22-24 | Initiated | Citigroup | Buy |
| Mar-01-24 | Initiated | Oppenheimer | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-23 | Initiated | UBS | Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Nov-01-22 | Initiated | Truist | Hold |
| Jul-29-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Nov-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-29-21 | Resumed | JP Morgan | Neutral |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Jul-06-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-05-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-05-18 | Resumed | Leerink Partners | Outperform |
| Jun-04-18 | Initiated | Piper Jaffray | Overweight |
| Apr-24-18 | Resumed | JP Morgan | Neutral |
| Sep-20-17 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-02-17 | Initiated | Robert W. Baird | Outperform |
| Mar-14-17 | Initiated | Oppenheimer | Outperform |
| Jan-13-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Oct-28-16 | Resumed | JP Morgan | Overweight |
| Aug-05-16 | Reiterated | FBR Capital | Outperform |
| Jul-26-16 | Initiated | Jefferies | Buy |
| Jul-13-16 | Reiterated | FBR Capital | Outperform |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Jan-06-16 | Initiated | Canaccord Genuity | Buy |
| Jun-30-15 | Initiated | Goldman | Buy |
| Jun-30-15 | Initiated | JP Morgan | Overweight |
| Jun-30-15 | Initiated | Leerink Partners | Outperform |
| Jun-30-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Evolent Health Inc Stock (EVH) Latest News
FY2024 EPS Estimates for Evolent Health Lowered by Analyst - MarketBeat
Evolent Health (NYSE:EVH) Trading 6.7% HigherTime to Buy? - MarketBeat
JPMorgan Chase & Co. Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price - MarketBeat
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025 - Nasdaq
Evolent Health Q4 Earnings Coming: Key Dates You Need to Know + 3 Major Conference Appearances - StockTitan
Oppenheimer Cuts Evolent Health (NYSE:EVH) Price Target to $18.00 - Defense World
Canaccord Genuity Group Cuts Evolent Health (NYSE:EVH) Price Target to $16.00 - Defense World
Evolent Health's SWOT analysis: healthcare tech stock faces challenges amid growth - MSN
Evolent Health's SWOT analysis: stock faces challenges amid growth potential By Investing.com - Investing.com South Africa
Canaccord cuts Evolent Health target to $16, maintains Buy - MSN
Evolent Health’s SWOT analysis: stock faces challenges amid growth potential - Investing.com Nigeria
Evolent Health (NYSE:EVH) Shares Gap Down on Analyst Downgrade - Defense World
JMP cuts Evolent Health target to $12, keeps Outperform rating - MSN
Evolent Health's SWOT analysis: stock faces challenges amid growth potential - MSN
Evolent Health’s SWOT analysis: healthcare tech stock faces challenges amid growth - Investing.com Nigeria
Evolent Health (NYSE:EVH) Shares Gap Down After Analyst Downgrade - MarketBeat
Brighton Jones LLC Makes New Investment in Evolent Health, Inc. (NYSE:EVH) - MarketBeat
Research Analysts’ Recent Ratings Changes for Evolent Health (EVH) - Defense World
Evolent Health's SWOT analysis: healthcare tech stock faces challenges amid growth By Investing.com - Investing.com South Africa
Canaccord Genuity Group Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price - MarketBeat
Evolent Health price target lowered to $20 from $29 at BTIG - Yahoo Finance
Stephens Lowers Evolent Health (NYSE:EVH) Price Target to $12.00 - Defense World
Evolent Health (NYSE:EVH) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Evolent Health (NYSE:EVH) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
Truist Financial Cuts Evolent Health (NYSE:EVH) Price Target to $15.00 - MarketBeat
Truist updates Evolent Health stock outlook on Q4 profitability adjustments - MSN
Truist updates Evolent Health stock outlook on Q4 profitability adjustments By Investing.com - Investing.com Canada
Stephens cuts Evolent Health stock target, retains equal weight rating - MSN
Evolent Health (NYSE:EVH) Price Target Lowered to $12.00 at Stephens - MarketBeat
Evolent Health, Inc. (NYSE:EVH) Receives $21.92 Average PT from Analysts - MarketBeat
Evolent Health, Inc. (NYSE:EVH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Evolent Health (NYSE:EVH) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Evolent Health (NYSE:EVH) Price Target Lowered to $14.00 at UBS Group - MarketBeat
Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics - MSN
Evolent Health FY2024 EPS Estimate Boosted by William Blair - Defense World
Evolent Health FY2024 EPS Forecast Lifted by William Blair - MarketBeat
Evolent Health (NYSE:EVH) Reaches New 12-Month LowHere's Why - MarketBeat
Evolent Health Stock Price (NYSE: EVH) Hit 52 Week Lows as Guidance Falls Short - AskTraders
Evolent Health (NYSE:EVH) Shares Down 2% After Analyst Downgrade - Defense World
Evolent Health (NYSE:EVH) Stock Price Down 2% Following Analyst Downgrade - MarketBeat
Evolent Health stock hits 52-week low at $10.52 amid market challenges - Investing.com Canada
Evolent Health stock hits 52-week low at $10.52 amid market challenges By Investing.com - Investing.com South Africa
What Analysts Are Saying About Evolent Health Stock - Benzinga
Evolent Health (NYSE:EVH) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Evolent Health (NYSE:EVH) Price Target Cut to $17.00 by Analysts at Royal Bank of Canada - MarketBeat
RBC adjusts Evolent Health price target, praises strong re-contracting efforts - Investing.com UK
Evolent Health Inc Stock (EVH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):